CSPC Pharmaceutical Group (HKG:1093) expects a 26% year-over-year decline in attributable profit for the year 2024 from around 5.87 billion yuan a year prior, a Tuesday filing with the Hong Kong bourse said.
The pharmaceutical firm attributed the lower anticipated profit mainly to a decrease in revenue of the finished drugs business.
Shares of the company were down nearly 4% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.